Molecules in Saliva May Hold the Key to Tracking Improvements in Autism
Molecules in the saliva may hold promise as a means to track the effectiveness of therapeutic interventions in children with autism spectrum disorder (ASD), according to a recently published study in the journal Research in Autism Spectrum Disorder.
Autism Biomarkers Could Save Billions in Healthcare Costs According to Recent Study
The use of accurate biomarkers for detecting autism spectrum disorder (ASD) could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research.
Saliva may hold key to concussion diagnosis and managment
A simple saliva swab may hold the key to diagnosing and managing mild traumatic brain injury (i.e., concussions), according to a study recently published in the journal Clinical and Translational Medicine.
Quadrant Biosciences Wins $2.3M NIH Grant to Develop Saliva Test for Concussion
Quadrant Biosciences said on Monday that it has received a $2.3 million grant from the National Institutes of Health to develop its saliva-based microRNA diagnostic test for concussions in children and adolescents.
Quadrant Biosciences Receives CPT® Proprietary Laboratory Analyses Code from the American Medical Association
Quadrant Biosciences Inc (Quadrant Biosciences) announced today that the American Medical Association (AMA) has issued a new CPT® Proprietary Laboratory Analyses (PLA) code for its Clarifi ASD™ autism saliva test.
Company That just Released World’s First Saliva Test for Autism Opens Up Investment Opportunity to the Public
Quadrant Biosciences Inc, a leading developer of epigenetic diagnostic solutions, including the world’s first saliva test for autism, announced that it is now offering common shares of the company (at a price of $3/share, with a minimum investment of $300) through equity crowdfunding platform Wefunder.
Quadrant Biosciences Teams up With Autism Speaks to Provide Support to Families and Healthcare Providers on the Path from Autism Diagnosis to Early Intervention
As part of its commitment to helping people with autism and their families and increasing early intervention through early diagnosis, Quadrant Biosciences announced today that they will support Autism Speaks’ mission with funding to expand delivery of reliable information, resources and support through the Autism Speaks Autism Response Team.
Quadrant Biosciences Partners with Leading Edge Genomic Testing Company Admera Health
Quadrant Biosciences Inc., an emerging life science company based in Syracuse, New York, is pleased to announce its strategic partnership with Admera Health, an advanced molecular diagnostics company headquartered in South Plainfield, NJ.
Motion Intelligence Inc. changes name to Quadrant Biosciences Inc. to Better Reflect Broader Business Focus
Motion Intelligence Inc. announced that it has changed its company name to Quadrant Biosciences Inc. The Syracuse, New York-based neuroscience company is involved in the development of functional assessments and epigenetic diagnostic solutions for large-scale health issues.